Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Certolizumab pegol in the treatment of spondyloarthritis
Submission date: 2014-05-19
Final revision date: 2014-07-23
Acceptance date: 2014-07-28
Online publication date: 2014-09-12
Publication date: 2014-08-31
Reumatologia 2014;52(4):263-268
KEYWORDS
TOPICS
Spondyloarthropaties - aetiology, pathogenesis clinical features and treatmentNew therapies in rheumatic diseases
ABSTRACT
Spondyloarthropaties (SpA) are a second common group of inflammatory rheumatic diseases after systemic connective tissue diseases. They are a frequent cause of disability. Tumor necrosis factor α (TNF-α) plays a crucial role in the initiation and continuation of chronic inflammation in SpA patients. Therefore, in case of high disease activity, despite treatment with non-steroidal anti-inflammatory drugs and/or synthetic disease modifying antirheumatic drugs, treatment with biologics is very efficacious. Certolizumab pegol is a one of the TNF inhibitors, with proven efficacy in the treatment of active SpA. This article summarizes basic data on certolizumab pegol, and results of clinical trials applied for the drug registration for the use in the management of patients with active SpA.
REFERENCES (28)
1.
Baeten D, Breban M, Lories R, Schett G, Sieper J. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013; 65: 12-20. .
2.
Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009; 68: 777-783. .
3.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368. .
4.
Sampaio-Barros PD, Bortoluzzo AB, Conde RA, et al. Undifferentiated spondyloarthritis: A longterm followup. J Rheumatol 2010; 37: 1195-1199. .
5.
Alnaeeli M, Teng YT. Dendritic cells: A new player in osteoimmunology. Curr Mol Med 2009; 9: 893-910. .
6.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357: 239-250. .
7.
FitzGerald O, McInnes I. Spondyloarthropathy: Disease at the crossroads of immunity. Best Pract Res Clin Rheumatol 2006; 20: 949-967. .
9.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
10.
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-908.
11.
Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236.
12.
Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-3412.
13.
van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-591.
14.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind,placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146.
15.
Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
16.
Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-3329.
17.
Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis 2009; 68: 805-811.
18.
Wiland P, Świerkot J, Maśliński W. Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów. Reumatologia 2011; 49: 253-263.
19.
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-1332.
20.
Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-279.
21.
Cimzia 200 mg solution for injection. [Internet].; 2012; cited 14 Dec 2012]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001037/WC500069763.pdf.
22.
Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10.
23.
Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009; 348: 36-41.
24.
Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
25.
Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2014 Apr 9 [in print]; doi: 10.1136/annrheumdis-2014-205322.
26.
Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73: 48-55.
27.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
28.
Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomisedplacebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-822.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
